OBJECTIVE: It has been shown that SOCS-1 plays an important role in the proper control of cytokine/growth factor responses and acts as a tumor suppressor in acute myeloid leukemias. Therefore, the objective of the present study was to evaluate the in vitro effect of treatment with Nutlin-3, a small molecule inhibitor of the MDM2/p53 interaction, on the expression of the suppressor of cytokine signaling 1 in primary acute myeloid leukemia cells and in myeloid cell lines with differential p53 status. METHOD: The expression of the suppressor of cytokine signaling 1 was quantitatively analyzed by real-time PCR in myeloid p53wild-type (OCI and MOLM) and p53null HL-60, leukemic cell lines, in patient-derived acute myeloid leukemia blasts, and ...
A range of cell types of mesenchymal origin express α-smooth muscle actin (α-SMA), a protein that pl...
ETV6/RUNX1 (E/R) is the most common fusion gene in childhood acute lymphoblastic leukemia. It is res...
In acute myeloid leukemia (AML), the restoration of p53 activity through MDM2 inhibition proved effi...
OBJECTIVE: It has been shown that SOCS-1 plays an important role in the proper control of cytokine/g...
AbstractThe small-molecule inhibitor of murine double minute (MDM-2), Nutlin-3, induced variable apo...
The small-molecule inhibitor of murine double minute (MDM-2), Nutlin-3, induced variable apoptosis i...
The small-molecule inhibitor of murine double minute (MDM-2), Nutlin-3, induced variable apoptosis i...
The basal SOCS1 mRNA levels were significantly lower in p53(mutated) BJAB and MAVER leukemic cell li...
PURPOSE: The oncogene TCL1 plays a key role in the development of B chronic lymphocytic leukemia (B-...
The small molecule inhibitor of the MDM2/p53 interaction Nutlin-3 significantly up-regulated the ste...
Background: The small-molecule MDM2 antagonist nutlin-3 has proved to be an effective p53 activating...
MDM2 is an important negative regulator of p53 tumor suppressor. In this study, we sought to investi...
The small molecule inhibitor of the MDM2/p53 interaction Nutlin-3 is a promising anti-cancer agent, ...
p53 is a tumour suppressor protein involved in maintenance of genomic stability of the cell. Primari...
The small molecule inhibitor of the MDM2/p53 interaction Nutlin-3 is a promising anti-cancer agent, ...
A range of cell types of mesenchymal origin express α-smooth muscle actin (α-SMA), a protein that pl...
ETV6/RUNX1 (E/R) is the most common fusion gene in childhood acute lymphoblastic leukemia. It is res...
In acute myeloid leukemia (AML), the restoration of p53 activity through MDM2 inhibition proved effi...
OBJECTIVE: It has been shown that SOCS-1 plays an important role in the proper control of cytokine/g...
AbstractThe small-molecule inhibitor of murine double minute (MDM-2), Nutlin-3, induced variable apo...
The small-molecule inhibitor of murine double minute (MDM-2), Nutlin-3, induced variable apoptosis i...
The small-molecule inhibitor of murine double minute (MDM-2), Nutlin-3, induced variable apoptosis i...
The basal SOCS1 mRNA levels were significantly lower in p53(mutated) BJAB and MAVER leukemic cell li...
PURPOSE: The oncogene TCL1 plays a key role in the development of B chronic lymphocytic leukemia (B-...
The small molecule inhibitor of the MDM2/p53 interaction Nutlin-3 significantly up-regulated the ste...
Background: The small-molecule MDM2 antagonist nutlin-3 has proved to be an effective p53 activating...
MDM2 is an important negative regulator of p53 tumor suppressor. In this study, we sought to investi...
The small molecule inhibitor of the MDM2/p53 interaction Nutlin-3 is a promising anti-cancer agent, ...
p53 is a tumour suppressor protein involved in maintenance of genomic stability of the cell. Primari...
The small molecule inhibitor of the MDM2/p53 interaction Nutlin-3 is a promising anti-cancer agent, ...
A range of cell types of mesenchymal origin express α-smooth muscle actin (α-SMA), a protein that pl...
ETV6/RUNX1 (E/R) is the most common fusion gene in childhood acute lymphoblastic leukemia. It is res...
In acute myeloid leukemia (AML), the restoration of p53 activity through MDM2 inhibition proved effi...